A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1

Elife. 2024 Apr 15:13:RP92379. doi: 10.7554/eLife.92379.

Abstract

A productive HIV-1 infection in humans is often established by transmission and propagation of a single transmitted/founder (T/F) virus, which then evolves into a complex mixture of variants during the lifetime of infection. An effective HIV-1 vaccine should elicit broad immune responses in order to block the entry of diverse T/F viruses. Currently, no such vaccine exists. An in-depth study of escape variants emerging under host immune pressure during very early stages of infection might provide insights into such a HIV-1 vaccine design. Here, in a rare longitudinal study involving HIV-1 infected individuals just days after infection in the absence of antiretroviral therapy, we discovered a remarkable genetic shift that resulted in near complete disappearance of the original T/F virus and appearance of a variant with H173Y mutation in the variable V2 domain of the HIV-1 envelope protein. This coincided with the disappearance of the first wave of strictly H173-specific antibodies and emergence of a second wave of Y173-specific antibodies with increased breadth. Structural analyses indicated conformational dynamism of the envelope protein which likely allowed selection of escape variants with a conformational switch in the V2 domain from an α-helix (H173) to a β-strand (Y173) and induction of broadly reactive antibody responses. This differential breadth due to a single mutational change was also recapitulated in a mouse model. Rationally designed combinatorial libraries containing 54 conformational variants of V2 domain around position 173 further demonstrated increased breadth of antibody responses elicited to diverse HIV-1 envelope proteins. These results offer new insights into designing broadly effective HIV-1 vaccines.

Keywords: combinatorial vaccine; cross-reactive antibodies; hiv escape; infectious disease; microbiology; mouse; v2 mutation.

MeSH terms

  • AIDS Vaccines* / genetics
  • Animals
  • Antibodies
  • Antibody Formation
  • Antigens, Viral
  • Dermatitis*
  • HIV-1* / genetics
  • Humans
  • Longitudinal Studies
  • Mice

Substances

  • AIDS Vaccines
  • Antibodies
  • Antigens, Viral